Introduction and Objective: In patients undergoing total pancreatectomy (TP), adequate glycemic control is a major concern. Previously, a 7-day treatment with a bihormonal artificial pancreas (BIHAP), delivering both insulin and glucagon for fully closed-loop regulation, improved glycemic control. However, evidence on its long-term efficacy is lacking.Methods: This randomised open-label crossover trial compared BIHAP treatment with […]
Read MoreMonth: June 2026
1233-OR: Postmeal Glucose Patterns as Early Predictors of Gestational Diabetes
Introduction and Objective: Gestational Diabetes Mellitus (GDM) screening at 24-28 weeks limits early intervention. Emerging studies, such as GLAM, have evaluated early screening using Continuous Glucose Monitoring (CGM) and standard metrics (e.g., TA140) as biomarkers, showing promising results. We hypothesize that novel features derived from post-prandial (PP) glucose profiles can outperform standard CGM metrics and […]
Read More1259-OR: Precise Carbohydrate Counting vs. Estimated Counting in Adults with Type 1 Diabetes Using mylife YpsoPump Advanced Hybrid Closed-Loop System: A Pilot Project Comparing Glycaemic Outcomes
Introduction and Objective: Carbohydrate counting is perceived as one of the most burdensome tasks in Type 1 Diabetes (T1D) but meta-analyses have shown it is an effective method in reducing HbA1c. We compared glycemic control in adults with T1D using mylife YpsoPump with advanced hybrid closed loop (HCL) system (mylife CamAPS FX app) among those […]
Read More1246-OR: Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, in Participants with and without Diabetes Mellitus in a Pooled Analysis of Two Phase 3 Trials
Introduction and Objective: Enlicitide is an oral PCSK9 inhibitor that, in two Phase 3 randomized, placebo-controlled trials, demonstrated LDL-C reduction of approximately 60% and was well tolerated. Here we report the efficacy of enlicitide in participants with and without diabetes mellitus (DM) at baseline, and the incidence of new onset or worsening diabetes.Methods: CORALreef Lipids […]
Read More1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial
Introduction and Objective: To evaluate the efficacy and safety of mazdutide 6 mg vs semaglutide 1 mg in Chinese T2D patients (pts) with obesity who had inadequately glycaemic control and suboptimal weight loss (WL) following lifestyle interventions with or without metformin (NCT06184568).Methods: A total of 349 pts aged ≥18 years with T2D duration ≤10 years […]
Read More1273-OR: Revolutionizing Cardiac Health: Unlocking the Power of Oral Ketones to Boost Cardiac Efficiency, Changes in Insulin Secretion, and Cardiometabolic Outcomes
Introduction and Objective: Heart Failure (HF) in T2D is common and increases mortality. IV Ketone infusion improves EF% ~6% at 3hrs in patients with T2D and HFrEF. Oral ketones (OKE) have shown similar results. Here, we evaluate the effect of chronic OKE administration (7 days) on cardiac efficiency.Methods: 12 subjects with T2D and HFrEF underwent […]
Read More1172-OR: Age-Specific Remote Education Facilitates Successful CGM Use in Older Adults with Diabetes Using Insulin
Introduction and Objective: CGM uptake remains limited in insulin-using older population in spite of data showing its effectiveness in improving glycemic control and lowering hypoglycemia risk. Whether remote education with strategies to overcome age-related barriers can improve adoption of CGM in older population is not known.Methods: In this prospective 6-month intervention study, we enrolled older […]
Read More1165-OR: Predictors of Diabetes Remission and Relapse after Metabolic Bariatric Surgery vs. Medical Lifestyle Intervention: The ARMMS-T2D Study
Introduction and Objective: Metabolic-bariatric surgery (MBS) is highly effective vs. medical-lifestyle intervention (MLI) for ameliorating T2D and promoting remission. Previous models of patient characteristics to predict T2D remission and relapse have used retrospective observational data, often without directly comparing different MBS procedures. The current study identifies clinical characteristics that predict T2D remission and relapse over […]
Read More1197-OR: Visceral Adipose Tissue ICOS hi Treg Cells Mitigates Systemic Metabolic Dysregulation in Diet-Induced Obese Mice
Introduction and Objective: Regulatory T (Treg) cells serve essential roles in immune tolerance and systemic tissue homeostasis remodeling under distinct physiological and pathological conditions. Visceral adipose tissue (VAT) Treg cells constitute a heterogeneous population capable of responding to diverse microenvironmental signals, however, the precise mechanisms by which VAT Treg cells regulate adipose tissue metabolic homeostasis […]
Read More1209-OR: Vagal Innervation, but Not the Hepatic Clock, Is Required for RYGB-Induced Glucose Improvement
Introduction and Objective: The molecular clock regulates energy balance and glucose metabolism. Roux-en-Y gastric bypass (RYGB) modulates these processes, but the underlying neural and hepatic mechanisms remain unclear. Prior findings show that RYGB in CLOCK-deficient mice blunts weight loss, fails to improve glucose homeostasis, and alters hepatic clock-gene rhythms independent of body weight. Because parasympathetic […]
Read More